• GPI Home
  • Solutions
    • GPI pulse™
    • GPI Consulting
    • GPI Horizon Methodology
    • Case Studies
  • About Us
    • Our Team
    • Careers
  • Contact Us
  • Discover
    • Blog
    • Events
    • Resources
  • GPI Direct
reimbursement
October 2, 2020 by Global Pricing Innovations (GPI)
Medicine Manufacturers Hit Hard by Latest French Healthcare Finance Reforms

Spending Changes Recently the French government has published its Social Security Finance Bill 2021 (PLFSS 2021), which covers the annual review of their health and social security expenditure. With the impact of COVID-19 increasing there seems to be an ever-increasing cost cutting exercise…

August 7, 2020 by Global Pricing Innovations (GPI)
Whitepaper: Indication based pricing – Widely advocated but not yet feasible

Find out how the notion of value based pricing methodologies are becoming more common place in pharmaceutical medicines pricing and how Indication-based pricing (IBP) has been proposed as a potential solution for any medicine that offers benefits across many different indications. In this…

March 20, 2020 by Global Pricing Innovations (GPI)
UPDATED – Webinar: Early Price and Access Forecasting (WFH Edition)

We hope you are all safe and in good health. At GPI, we are extremely proud to present our new offering, GPI HORIZON, an innovative methodology supporting early price and access forecasting. Despite the uncertainty and change brought by COVID-19 outbreak, GPI have…

March 17, 2020 by Global Pricing Innovations (GPI)
GPI makes market access more efficient with pioneering partnership with Sisense-enabled analytics platform

Pricing & Market Access leader enhances pricing database with world’s leading analytics platform for technology developers  London, UK, March 17, 2020 – Global Pricing Innovations (GPI), a leader in analytical market access solutions for biopharma, has announced the Spring 2020 release of new features…

SiSense Logo
GPI Pulse used in Spain
March 10, 2020 by Global Pricing Innovations (GPI)
Spain introduces exclusive pricing scheme for new orphan drugs. How will this affect International Reference Pricing?

Author – Nairuti Patel (Associate Consultant, GPI) On 3rd March 2020, the Spanish Council of Ministers announced a ‘specific pricing system’ for orphan medicinal product that will be separate from the reference pricing system. The reference pricing system applies to all other products reimbursed by the Spanish National Health System (SNS) when their patent has expired. The only instance when orphan drugs will be included in this new…

February 25, 2020 by Global Pricing Innovations (GPI)
GPI will be sponsoring the drinks reception at World Pharma Pricing Market Access & Evidence Congress 2020

Global Pricing Innovations will be sponsoring the drinks reception at World Pharma Pricing Market Access and Evidence Congress 2020 on the 18th March 2020 at Amsterdam’s Beurs van Berlage venue. GPI will be officially launching and providing an exclusive sneak peak at our…

GPI is the sponsor of the drinks reception at PPMA 2020. Join us on the 18th of march!
Novartis Building
February 20, 2020 by Global Pricing Innovations (GPI)
Capmatinib: The Race to Approval and Optimal Pricing

By Ines Dieringer – Associate Consultant With new mutations which are driving oncogenesis in life-threatening cancers being discovered everyday, the industry looks be keeping pace with targeted therapies for these mutagenic targets. One such example is Novartis’ investigational therapy Capmatinib. This investigational therapy…

February 18, 2020 by Global Pricing Innovations (GPI)
GPI attending World Pharma Pricing, Market Access and Evidence Congress

Global Pricing Innovations will be attending the World Pharma Pricing, Market Access & Evidence Congress in Amsterdam on the 18th and 19th March 2020. Please reach out to our Business Development Manager to arrange a meeting at the event. Musa Kureshy – Business…

GPI will be attending PPMA 2020. See you there!
April 8, 2019 by Global Pricing Innovations (GPI)
Harmonisation of HTA practice: Underlying methodological differences across HTA agencies that impact national list prices

By Alexandros Soumalevris, GPI     Working towards Health Technology Assessment (HTA) harmonisation There have been calls for the European Union (EU) countries, the European Parliament and other interested parties initiated in 2016 to the European Commission, to work on strengthening EU cooperation…

Our partners
  • Privacy Policy
  • Terms of Use

| © Copyright 2018 Global Pricing Innovations. All Rights Reserved.

VAT registration: GB225169121